SCM
ANIP icon

Sarissa Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Sarissa Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-31,000
Closed -$1.4M – 18
2015
Q4 		$1.4M Hold
31,000
– – 0.27% 15
2015
Q3 		$1.23M Hold
31,000
– – 0.3% 16
2015
Q2 		$1.92M Hold
31,000
– – 0.44% 14
2015
Q1 		$1.94M Hold
31,000
– – 0.41% 15
2014
Q4 		$1.75M Buy
+31,000
New +$1.37M 0.62% 12

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

Sarissa Capital Management's ANIP Position: Q1 2016 in Review

Sarissa Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2016, closing a stake of 31,000 shares — an estimated $1.4M sold.

Sarissa Capital Management first reported a position in ANIP in Q4 2014 and held it in 5 quarters. The position peaked at $1.94M in Q1 2015. 121 funds tracked by Wall St. Rank hold ANIP as of Q1 2016.

  • Sarissa Capital Management reported no remaining ANI Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Sarissa Capital Management sold 31,000 ANI Pharmaceuticals shares in Q1 2016, an estimated $1.4M.
  • Sarissa Capital Management first reported a position in ANI Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Sarissa Capital Management's ANI Pharmaceuticals position peaked at $1.94M in Q1 2015.
  • 121 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2016.

Based on Sarissa Capital Management's 13F filing for Q1 2016, filed 16 May 2016.